Chronic kidney disease and an uncertain diagnosis of Fabry disease: Approach to a correct diagnosis

Linda van der Tol(Amsterdam UMC Location University of Amsterdam), Gabor E. Linthorst(Amsterdam UMC Location University of Amsterdam), Robin Lachmann(University College London), Derralynn Hughes(Royal Free London NHS Foundation Trust), João Paulo Oliveira(Universidade do Porto), Wim Terryn(Ghent University Hospital), Carla E. M. Hollak(Amsterdam UMC Location University of Amsterdam), Einar Svarstad(Haukeland University Hospital), Christoph Wanner(University of Würzburg), Sandrine Florquin(Academic Medical Center), Liffert Vogt(Amsterdam University College), Camilla Tøndel(Haukeland University Hospital), Michael L. West(Dalhousie University), Alberto Ortíz(Fundación Renal), Stephen Waldek, Marieke Biegstraaten(Amsterdam UMC Location University of Amsterdam), Marius A. van den Bergh Weerman(Amsterdam UMC Location University of Amsterdam)
Molecular Genetics and Metabolism
August 20, 2014
10.1016/j.ymgme.2014.08.007
Cited by 64

Related Papers

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
|New England Journal of Medicine|2016|3.6k
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
|New England Journal of Medicine|2013|990
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
|The Lancet|2022|969
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
|The Lancet|2010|905
Elevated globotriaosylsphingosine is a hallmark of Fabry disease
|Proceedings of the National Academy of Sciences|2008|725